Whitepapers

Will the Inflation Reduction Act transform the generic drug market and disrupt cost savings? Our white paper explores the potential impact of the IRA on generics. Learn how CMS drug price negotiations, revenue shifts, and market access challenges could reshape the landscape.

China’s biopharma sector has ascended to global prominence, building innovation capabilities and a pipeline second only to the U.S. However, its rapid success has created an “overcapacity” of innovation, outpacing the commercial capacity of the domestic market. Because of current cost-control constraints and regulatory tensions, Chinese patients have limited access to Chinese-developed therapeutics, and biopharma companies struggle to capitalize on their innovations domestically. China is becoming a victim of its own success.

Understanding the longterm effects of medications is essential for ensuring patient safety and optimizing healthcare outcomes. However, comprehensive longitudinal data to study effects of drugs over extended periods can be hard to come by.